Intellia Therapeutics announced it will present seven studies, including four-year follow-up data on lonvoguran ziclumeran (lonvo-z), a one-time CRISPR gene editing treatment for hereditary angioedema (HAE), at the ACAAI 2026 meeting. The company will also host an investor webcast on November 12 to discuss the data and preparations for lonvo-z's planned commercial launch. Lonvo-z aims to permanently reduce kallikrein levels with a single outpatient dose and has received multiple regulatory designations. The FDA is reviewing its Biologics License Application with a decision expected by March 10, 2027.
Intellia Therapeutics' upcoming investor event and presentations come as the Health sector on Pluang shows broad activity, with 95 of 150 US health stocks rising as of Oct 29, 2026 18:11 WIB. Notable movers include Teladoc Health Inc (TDOC), which gained 13.81%, Haleon plc (HLN), down 14.20%, and Iovance Biotherapeutics Inc (IOVA), which saw 100% sell order activity and a 9.52% price drop. This snapshot reflects diverse investor interest and trading dynamics in the health sector on Pluang.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
